Long-term humoral signatures following acute pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children
Authors:
Open Access
- 12 May 2023
- journal article
- research article
- Published by Springer Nature in Pediatric Research
- Vol. 94 (4) , 1327-1334
Abstract
Background Although most children experience mild symptoms during acute SARS-CoV-2 infection, some develop the severe post-COVID-19 complication, Multisystem Inflammatory Syndrome in Children (MIS-C). While acute presentations of COVID-19 and MIS-C have been well immunophenotyped, little is known about the lasting immune profile in children after acute illness. Methods Children 2 months–20 years of age presenting with either acute COVID-19 (n = 9) or MIS-C (n = 12) were enrolled in a Pediatric COVID-19 Biorepository at a single medical center. We deeply profiled humoral immune responses and circulating cytokines following pediatric COVID-19 and MIS-C. Results Twenty-one children and young adults provided blood samples at both acute presentation and 6-month follow-up (mean: 6.5 months; standard deviation: 1.77 months). Pro-inflammatory cytokine elevations resolved after both acute COVID-19 and MIS-C. Humoral profiles continue to mature after acute COVID-19, displaying decreasing IgM and increasing IgG over time, as well as stronger effector functions, including antibody-dependent monocyte activation. In contrast, MIS-C immune signatures, especially anti-Spike IgG1, diminished over time. Conclusions Here, we show the mature immune signature after pediatric COVID-19 and MIS-C, displaying resolving inflammation with recalibration of the humoral responses. These humoral profiles highlight immune activation and vulnerabilities over time in these pediatric post-infectious cohorts. Impact The pediatric immune profile matures after both COVID-19 and MIS-C, suggesting a diversified anti-SARS-CoV-2 antibody response after resolution of acute illness. While pro-inflammatory cytokine responses resolve in the months following acute infection in both conditions, antibody-activated responses remain relatively heightened in convalescent COVID-19. These data may inform long-term immunoprotection from reinfection in children with past SARS-CoV-2 infections or MIS-C.Keywords
This publication has 29 references indexed in Scilit:
- HLA class I–associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in childrenJournal of Clinical Investigation, 2021
- Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19JAMA, 2021
- Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19Science Immunology, 2021
- Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in ChildrenJAMA, 2021
- Humoral signatures of protective and pathological SARS-CoV-2 infection in childrenNature Medicine, 2021
- Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune ResponsesThe Journal of Pediatrics, 2020
- Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrumNature Immunology, 2020
- Establishment of a pediatric COVID-19 biorepository: unique considerations and opportunities for studying the impact of the COVID-19 pandemic on childrenBMC Medical Research Methodology, 2020
- Multisystem Inflammatory Syndrome in U.S. Children and AdolescentsNew England Journal of Medicine, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020